Publish in OALib Journal
APC: Only $99
Lung cancer is one of the most
aggressive and lethal form of cancers. Patients with far advanced lung cancer
are treated by chemotherapy with or without radiotherapy. However, median
survival of these patients is less than 6 months. To increase survival and
quality of life for these patients, various forms of complementary treatments
have been tried in clinical practices, and oncothermia is supposed to be one of
the promising candidates. From May 2008 to November 2013, 4 patients with far
advanced lung adenocarcinoma (stages IIIB and IV) were treated with oncothermia
in addition to conventional chemotherapy at Gangnam Severance Hospital and
Bundang CHA Hospital. All these patients have survived for more than 2 years.
Current dialysis systems are not perfect
considering the low efficacy and cumbersome process of actual practice. To
overcome these shortcomings, bioartificial kidneys using renal tubule cells and
wearable dialysis are promising ESRD treatments available in the near future.
Toward clinical application, however, there are so many obstacles for
commercial use of them. In this review, current status of bioartificial kidneys
such as the renal tubule cell assist device (RAD) and wearable dialysis devices
is presented with the comparison to show the advantages and disadvantages.